

ISSUE @ A GLANCE



Dyslipidaemias and cardiovascular diseases: beyond cholesterol and atherosclerotic plaques
F. Crea

3865

CardioPulse

The new Dyslipidaemia Team of the European Heart Journal
S.L. Tokgözoğlu, C.E. Orringer, and A.L. Catapano

3870

The European Heart Journal - Digital Health
N. Bruining

3871

ESC Congress 2020 - Young Investigator Awards
M. Nicholls

3873

COVID-19 pandemic in India
V.S. Ram, G.R. Babu and D. Prabhakaran

3874

Czech Republic and low COVID-19 mortality in the heart of Europe: possible explanations
P. Widimsky, J. Benes, and A.M. Celko

3876

Weekly Journal Scan

Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trial
G. Liuzzo and C. Patrono

3880

EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial
G. Liuzzo and C. Patrono

3881

Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial
G. Liuzzo and C. Patrono

3882

STATE OF THE ART REVIEW

From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases
U. Landmesser, W. Poller, S. Tsimikas, P. Most, F. Paneni, and T.F. Lüscher

3884

CLINICAL RESEARCH

Dyslipidaemias

 **Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation study**
A. Allahyari, T. Jernberg, E. Hagström, M. Leosdottir, P. Lundman, and P. Ueda

3900

Editorial

Real-world data, theoretical application of guidelines, cost, and access: how do we optimize non-statin therapy for LDL-C/non-HDL-C/ApoB?
C.M. Ballantyne and S.S. Virani

3910

Dyslipidaemias

 **Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study**
M. Nazarzadeh, A.-C. Pinho-Gomes, Z. Bidel, A. Dehghan, D. Canoy, A. Hassaine, J.R. Ayala Solares, G. Salimi-Khorshidi, G.D. Smith, C.M. Otto, and K. Rahimi

3913

Editorial


Lipid levels linked to symptomatic aortic valve stenosis: evidence from Mendelian randomization?
C.A. Nienaber and X. Yuan

3921

Dyslipidaemias

- Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial
M.J. Budoff, D.L. Bhatt, A. Kinnering, S. Lakshmanan, J.B. Muhlestein, V.T. Le, H.T. May, K. Shaikh, C. Shekar, S.K. Roy, J. Tayek, and J.R. Nelson

3925



Editorial

Can EPA evaporate plaques?


L. Tokgozoglu and A.L. Catapano

3933

Dyslipidaemias

- Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to *ANGPTL3* mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
D. Gaudet, E. Karwatowska-Prokopczuk, S.J. Baum, E. Hurh, J. Kingsbury, V.J. Bartlett, A.L. Figueroa, P. Piscitelli, W. Singleton, J.L. Witztum, R.S. Geary, S. Tsimikas, and L. St. L. O'Dea; for the Vupanorsen Study Investigators

3936



Editorial

Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on *ANGPTL3*

U. Landmesser and T.F. Lüscher

3946

TRANSLATIONAL RESEARCH

Dyslipidaemias

The haemochromatosis gene *Hfe* and Kupffer cells control LDL cholesterol homeostasis and impact on atherosclerosis development

E. Demetz, P. Tymoszyk, R. Hilbe, C. Volani, D. Haschka, C. Heim, K. Auer, D. Lener, L.B. Zeiger, C. Pfeifhofer-Obermair, A. Boehm, G.J. Obermair, C. Ablinger, S. Coassin, C. Lamina, J. Kager, V. Petzer, M. Asshoff, A. Schroll, M. Nairz, S. Dichtl, M. Seifert, L. von Raffay, C. Fischer, M. Barros-Pinkelning, N. Brigo, L. Valente de Souza, S. Sopfer, J. Hirsch, M. Graber, C. Gollmann-Tepeköylü, J. Holfeld, J. Halper, S. Macheiner, J. Gostner, G.F. Vogel, R. Pechlaner, P. Moser, M. Imboden, P. Marques-Vidal, N.M. Probst-Hensch, H. Meiselbach, K. Strauch, A. Peters, B. Paulweber, J. Willeit, S. Kiechl, F. Kronenberg, I. Theurl, I. Tancevski, and G. Weiss

3949

Editorial

Role of homeostatic iron regulator protein in hepatic cholesterol metabolism: interaction between Kupffer cells and hepatocytes?

L.L. Blauw and P.C.N. Rensen

3960

DISCUSSION FORUM

Life course explains the 'obesity paradox'?

T.E. Strandberg and A.Y. Strandberg

3963

The obesity paradigm in cardiovascular disease: the need for differentiated weight management

W. Doehner, S. Hess, and H.C. Gerstein

3965

CARDIOVASCULAR FLASHLIGHT

Percutaneous closure of right coronary artery to the left ventricle coronary cameral fistula in a case of congenitally absent left coronary artery

V.S. Thomson, S.T. Chacko, G. Joseph, and L.R. Vimala

3966

ERRATUM

Erratum to: The PROFID project

3948

 Open Access Paper



For the podcast associated with this article, please visit <https://academic.oup.com/eurheartj/pages/Podcasts>



Visit EHJ's mobile site
<https://academic.oup.com/eurheartj>



www.eurheartj.org